KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CareDx (CDNA) Cash & Equivalents (2016 - 2025)

CareDx's Cash & Equivalents history spans 13 years, with the latest figure at $65.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 42.95% year-over-year to $65.4 million; the TTM value through Dec 2025 reached $65.4 million, down 42.95%, while the annual FY2025 figure was $65.4 million, 42.95% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $65.4 million at CareDx, down from $91.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $353.1 million in Q3 2021 and bottomed at $65.4 million in Q4 2025.
  • The 5-year median for Cash & Equivalents is $92.4 million (2024), against an average of $144.6 million.
  • The largest annual shift saw Cash & Equivalents surged 860.9% in 2021 before it plummeted 76.5% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $348.5 million in 2021, then tumbled by 74.2% to $89.9 million in 2022, then decreased by 8.59% to $82.2 million in 2023, then skyrocketed by 39.53% to $114.7 million in 2024, then tumbled by 42.95% to $65.4 million in 2025.
  • Per Business Quant, the three most recent readings for CDNA's Cash & Equivalents are $65.4 million (Q4 2025), $91.4 million (Q3 2025), and $68.2 million (Q2 2025).